OncLive TV

Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses investigational strategies to mitigate belantamab mafodotin-blmf–related keratopathy in multiple myeloma.

Wenyin Shi, MD, PhD, discusses the rationale to evaluate a tumor-treating fields therapy in combination with temozolomide and radiation therapy in glioblastoma.

Julie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.

William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

Tadeusz Robak, MD, PhD, discusses the inclusion criteria of the the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

John L. Marshall, MD, discusses the results of the phase 2 DESTINY-Gastric02 trial in HER2-positive gastric and gastroesophageal junction cancers.

Syed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.

Mark Yarchoan, MD, discusses unique characteristics of fibrolamellar carcinoma.

Timothy F. Burns, MD, PhD, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer.

Liza C. Villaruz, MD, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer.

William G. Wierda, MD, PhD, discusses efforts to examine fixed-duration treatment strategies in patients with chronic lymphocytic leukemia.

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation. 

Rachna T. Shroff, MD, discusses the importance of targeted therapy in advanced biliary tract cancer.

John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Sumit K. Subudhi, MD, PhD, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer.

Matthew S. McKinney, MD, discusses the expanding role of BTK inhibitors in mantle cell lymphoma.

Jason Brayer, MD, PhD, discusses the emergence of bispecific T-cell engagers and bispecific antibodies in multiple myeloma.

Alexey V. Danilov, MD, PhD, discusses the safety profile of entospletinib plus obinutuzumab in chronic lymphocytic leukemia.

David Zhen, MD, discusses the need for novel therapies in poorly differentiated small-cell-type neuroendocrine tumors.

Irene Ghobrial, MD, discusses future efforts to prevent the development of multiple myeloma. 

Meghan Thompson, MD, discusses the safety profile of pirtobrutinib in patients with Richter transformation.

Chan Cheah, MBBS, discusses the toxicity profile of TG-1701 with and without ublituximab and umbralisib in patients with chronic lymphocytic leukemia.

Jay Moon Lee, MD, discusses the current state of molecular testing in early-stage non–small cell lung cancer.

Sandip P. Patel, MD, discusses the utility of consolidative durvalumab in stage III non–small cell lung cancer.

Angeles A. Secord, MD, discusses the design of the phase 3b OReO trial in ovarian cancer.

Sikander Ailawadhi, MD, discusses the rationale for evaluating lisaftoclax in chronic lymphocytic leukemia in an early phase 1 study.

Heloisa P. Soares, MD, PhD, discusses advances in the management of pancreatic neuroendocrine tumors.

Amado J. Zurita-Saavedra, MD, discusses moving therapies utilized in metastatic castration-resistant prostate cancer into the treatment of patients with metastatic hormone-sensitive prostate cancer.